Due to safety concerns, the pharmaceutical industry has long avoided covalent drug approaches. More recent success stories have shown that carefully tuned reactivity and specific complementarity of covalent compounds to their target can give rise to drugs with a range of advantages, particularly in the cancer field.
In this upcoming educational webinar, leading scientists will discuss the biochemical strategies for characterizing covalent compounds in vitro, exemplified by the recent discovery of a new covalent inhibitor targeting the hitherto undruggable cancer target USP7.
It will be presented by Dr. Agnes Martin, a principal scientist in the Screening and Compound Profiling group at Cancer Research UK’s Therapeutic Discovery Laboratories, specializing in biochemical and biophysical assay development for small molecule hit identification and validation. She will be joined by Catherine Wark, a senior applications scientist with over 15 years’ experience at BMG Labtech, assisting users with microplate reader and assay optimization.
Register for this webinar to learn how:
Attend the live webinar on Monday, June 4, at:
If you can’t attend the live event, register to watch the webinar on demand at a time that suits you